Drug detection test kit RIDASCREEN®

serumplasmaELISA

The RIDASCREEN® VDZ Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of vedolizumab (VDZ, Entyvio®, anti- integrin α4β7) in human serum and plasma. Product information Vedolizumab (VDZ, Entyvio®) is approved for the treatment of patients with moderate to severe Crohn’s disease and ulcerative colitis in whom conventional therapy or anti-TNFα therapies were ineffective or not tolerated. It is a gut-specific, humanized monoclonal antibody targeting the α4β7-integrin protein, which is involved in the migration of lymphocytes to the gut. Similar as to anti-TNFα drugs, measurement of vedolizumab drug concentrations supports a personalized dosing strategy in patients treated with vedolizumab. The RIDASCREEN® VDZ Monitoring and our other TDM assays are vital to personalize treatment of patients with Crohn’s disease and ulcerative colitis and better achieve therapeutic targets. Key features: CE-marked version of the ELISA tests of KU Leuven Highly specific antibodies Ready to use reagents Validated for use on automated ELISA systems, e.g. the Dynex DSX®